Earnings Scheduled For May 4, 2026

Pulse Biosciences Q1 EPS $(0.27) Beats $(0.32) Estimate, Sales $401.000K Beat $400.000K Estimate

Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.32) by 12.9 percent. This is a 8 percent decrease over losses of $(0.25) per share from the

Reported Saturday, Pulse Biosciences' nPulse Cardiac Catheter System Delivers 90% Kaplan-Meier Freedom From AF At One Year In Expanded 53-Subject Follow-Up Cohort

Pulse Biosciences Appoints Liane Teplitsky As Chief Operating Officer And Dr. David Kenigsberg As Chief Medical Officer

12 Health Care Stocks Moving In Tuesday's Intraday Session

Pulse Biosciences Enrolls First Patient In Its NANOPULSE-AF Study Of nPulse Cardiac Catheter System For Recurrent, Drug-Resistant, Symptomatic Paroxysmal Atrial Fibrillation

The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research Group. "This is a